ClinicalTrials.gg
CompletedNCT04437498VNS mTBIUpdated Nov 2, 2026

Vagal Nerve Stimulation in mTBI

An interventional study of sham stimulation and nVNS in PTSD and mTBI, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Now CompletedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development — 56 open to participants now, 65 under way, 4 of them phase 3. Stress Disorders, Post-Traumatic · VA Office of Research and Development.

Enrollment
208th of 246
28 · median 87
Started
2021
with 19 others
No phase
185 of 263
42 open now
Registered
174th of 263
by date

Among the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, this one is the 208th largest by enrollment of the 246 interventional ones that give a count, is one of 20 that started in 2021, is one of 185 with no phase, and was the 174th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

56 of the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

51 more — sign in →

By country, each count listing its studies:

All 56 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, or all of them as a file.
02

Study summary

Mild traumatic brain injury (mTBI) and posttraumatic stress disorder (PTSD) are important conditions for the Veterans Administration (VA) that frequently occur together in combat Veterans from the conflicts in Afghanistan and Iraq. In many Veterans these become chronic, raising the risk the burden of neurotrauma can worsen over time. This study will examine a new intervention called non-invasive Vagal Nerve Stimulation (nVNS) and its effects on memory and symptoms of PTSD and mTBI as well as brain and physiology in Veterans with mTBI and PTSD.

Read the detailed description

This projects will assess the effects of non-invasive Vagal Nerve Stimulation (nVNS) on neurobiology and cognition in combat Veterans with mild Traumatic Brain Injury (mTBI) and co-morbid posttraumatic stress disorder (PTSD) during the performance of stressful tasks (traumatic scripts, mental arithmetic) and verbal declarative memory tasks using measurement of memory performance, peripheral inflammatory markers in blood (IL6) and cardiovascular responses using wearable gated sensing devices and electro- and seismocardiography, as well as brain response (anterior cingulate, hippocampus) measured with High Resolution Positron Emission Tomography (HR-PET) and radiolabelled water (15O[H2O]). The investigators hypothesize that nVNS but not sham control will result in enhanced memory, and hippocampal activation with memory encoding, and reduced cardiovascular, sympathetic, and inflammatory responses to stress. The investigators will also assess the effects of nVNS and sham on memory retention when applied to the encoding phase of a declarative memory learning task repeated daily over a four day period and on ratings of PTSD and pain in Veterans with mTBI and co-morbid PTSD and repeat assessments after three months of twice daily treatments.

03

Conditions studied

  • PTSD
  • mTBI

Keywords

  • vagus nerve
  • stress disorders, posttraumatic
  • traumatic brain injury
  • memory
  • hippocampus
  • emission tomography
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veterans with Mild Traumatic Brain Injury (mTBI) and post-Traumatic Stress Disorder (PTSD)

Exclusion criteria

Exclusion Criteria:

  • amnesia for the inciting event lasted longer than 24 hours
  • Glasgow Coma Scale Score after 30 minutes was less than 13
  • loss of consciousness more than 30 minutes
  • positive pregnancy test
  • meningitis or other neurological disorder other than Mild Traumatic Brain Injury (mTBI)
  • alcohol or substance abuse use disorder based on the SCID within the past 12 months
  • current or lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, anorexia nervosa or bulimia, based on the SCID
  • active suicidal ideation based on criteria outlined below
  • a history of serious medical or neurological illness, such as cardiovascular, gastrointestinal, hepatic, renal, neurologic or other systemic illness
  • active neuroleptic, opiate, or benzodiazepine treatment
  • structural abnormality on brain magnetic resonance imaging (MRI) or computed tomography (CT)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    nVNS

    non invasive vagal nerve stimulation

    Device: nVNS

  • Sham comparator
    sham

    sham stimulation

    Device: sham stimulation

Interventions

  • Devicesham stimulation

    non invasive vagal nerve stimulation

  • DevicenVNS

    active vns stimulation

06

What researchers measure

Primary outcomes

  1. CAPS

    The Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS) is a measure of PTSD symptoms with a range of 0-80 and higher score indicating more severe PTSD symptoms. The investigators will compare change from baseline to post treatment with active vagal nerve stimulation (VNS) or sham stimulation twice daily.

    Time frame: three months

  2. Insula

    Blood flow in the insula is measured with positron emission tomography (PET) and radiolabelled water during the performance of stress tasks. The investigators will compare blood flow in the insula to whole brain blood flow ratio during stress tasks (listening to personalized traumatic scripts) versus control tasks in the VNS versus sham groups with hypothesis of blocked insula blood flow with VNS

    Time frame: 10 minutes

  3. HVLT-R % retention

    The Hopkins Verbal Learning Test-Revised (HVLT-R) is a test of declarative memory learning that involves the learning of 12 nouns, four from each of three semantic categories, learned over three learning trials, followed 20 minutes later by a delayed free recall trial and recognition trial composed of 24 words with 12 false positives. The percent (%) retention is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3. HLVT-R % retention has a range of 0-100 with 100 being best and 0 worst performance. Baseline and three months post treatment paired with sham or active stimulation are compared.

    Time frame: baseline versus three months

  4. Change in IL6 Concentration in Blood with Stress

    Interleukin-6 (IL6) response to stress paired with active or sham stimulation. IL6 is an inflammatory biomarker measured in blood. The investigators will compare IL6 response to stress in VNS versus sham treated groups.

    Time frame: Baseline to 120 minutes after stress

  5. Hippocampal activation

    Blood flow in the hippocampus is measured with positron emission tomography (PET) and radiolabelled water during the performance of declarative memory tasks. The investigators will compare blood flow in the hippocampus to whole brain blood flow ratio during memory tasks versus control tasks in the VNS versus sham groups with hypothesis of increased hippocampal blood flow with VNS

    Time frame: 10 minutes

Secondary outcomes

  1. PPG amplitude

    Photoplethysmography (PPG) amplitude is a measure of peripheral vasoconstriction which is a marker of sympathetic response to stress with active or sham. PPG amplitude is the diameter of the blood vessel in the finger, the investigators will measure change from baseline to post active vagal nerve stimulation versus sham stimulation with stress.

    Time frame: Change from baseline to 5 seconds after the termination of stimulation paired with stress

07

Study locations

1 site
  • Atlanta VA Medical and Rehab Center, Decatur, GA
    Decatur, Georgia 30033-4004, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: three months after study end

Access criteria: de identified data for three years

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jul 2026, 64 months.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 64 months is above that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2026 → Jul 2026 and completion Dec 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2020
First posted
Jun 18, 2020
StartActual
Feb 25, 2021
Primary completionActual
Jul 1, 2026was Dec 2026
CompletionActual
Jul 1, 2026was Dec 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 26, 2026
Primary completion
Dec 10, 2026→Jul 1, 2026 (actual)
Oct 26, 2026
Study completion
Dec 10, 2026→Jul 1, 2026 (actual)
Oct 26, 2026
Enrollment
100 (estimated)→28 (actual)
Oct 26, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Veterans with mTBI and PTSDNow Veterans with Mild Traumatic Brain Injury (mTBI) and post-Traumatic Stress Disorder (PTSD)
Exclusion criteria
  • Editedmeningitis or other neurological disorder other than Mild Traumatic Brain Injury (mTBI)
  • Editedstructural abnormality on brain magnetic resonance imaging (MRI) or computed tomography (CT)
Oct 26, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedinsulaInsulaTime frame: 10 minutes
  • EditedhippocampalHippocampal activationTime frame: 10 minutes
Oct 26, 2026
Documents
Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Documents Informed consent form ↗ posted
  2. Oct 26, 2026
    Recruiting→Completed
    Primary completion Dec 10, 2026→Jul 1, 2026 (now actual)
    Study completion Dec 10, 2026→Jul 1, 2026 (now actual)
    Enrollment 100 (estimated)→28 (actual)
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Veterans with mTBI and PTSDNow Veterans with Mild Traumatic Brain Injury (mTBI) and post-Traumatic Stress Disorder (PTSD)
    Exclusion criteria
    • Editedmeningitis or other neurological disorder other than Mild Traumatic Brain Injury (mTBI)
    • Editedstructural abnormality on brain magnetic resonance imaging (MRI) or computed tomography (CT)
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedinsulaInsulaTime frame: 10 minutes
    • EditedhippocampalHippocampal activationTime frame: 10 minutes
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04437498
Collaborators
Atlanta VA Medical Center
Responsible party
Sponsor
First posted
Jun 18, 2020
Start date
Feb 25, 2021
Primary completion
Jul 1, 2026
Completion
Jul 1, 2026
Last update
Nov 2, 2026

Study contacts

Doug J Bremner, MD
principal investigator · Atlanta VA Medical and Rehab Center, Decatur, GA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion